Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta for relapsing multiple sclerosis following reports of inflammatory encephalitis and meningoencephalitis.

Biogen will continue to work collaboratively with regulatory authorities in the withdrawal from market and with healthcare providers worldwide in their support of Zinbryta patients. Patients currently treated with Zinbryta should contact their healthcare provider if they have any questions or concerns.